COR vs MCK: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

MCK is the larger of the two ($123.64B market cap): the incumbent the market prices for continued execution (20.56x forward earnings, beta 0.28). COR is the smaller challenger ($65.89B), cheaper on forward earnings (15.91x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

COR vs MCK: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricCORMCKWhat it tells you
Market cap$65.89B$123.64BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E15.9120.56Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E19.2327.62Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.570.28Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range76% of range87% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.

Reading it: COR is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how COR and MCK affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. COR and MCK share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined COR and MCK exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Cencora, Inc. (COR) do?

Cencora buys pharmaceuticals from manufacturers and delivers them to pharmacies, hospitals, physician practices and clinics, taking a fee measured in fractions of a percent on each transaction. Roughly 90 percent of revenue sits in the U.S. Healthcare Solutions segment, where specialty products (oncology drugs, biologics, cell and gene therapies) carry better economics than traditional generics and now anchor the growth rate. International Healthcare Solutions covers distribution and specialty logistics across Europe and Canada, and the smaller Other segment holds MWI Animal Health and Brazil's Profarma. The company employs roughly 47,000 people and was known as AmerisourceBergen until August 2023.

Full COR guide

What does McKesson Corporation (MCK) do?

McKesson Corporation is a healthcare-services and pharmaceutical-distribution company, one of the "Big Three" US drug wholesalers alongside Cencora (formerly AmerisourceBergen) and Cardinal Health that together handle the large majority of prescription drugs sold in the country. In fiscal 2026 (ended March 2026) the company reported roughly $403 billion in revenue, and trailing revenue has since reached about $411 billion, the bulk of it from its North American Pharmaceutical segment, which sources, warehouses, and delivers branded, generic, and specialty medicines to pharmacies, health systems, and providers. Because distribution is a scale game with very low margins, McKesson competes on logistics efficiency, breadth of contracts, and reliability rather than pricing power on the drugs themselves.

Full MCK guide

COR vs MCK: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • COR drivers: Specialty volume, not overall drug volume; Moving downstream into provider services.
  • MCK drivers: Defensive, volume-driven distribution core; Specialty and oncology services mix-shift.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Customer concentration is the sharpest exposure: a small number of relationships, including Walgreens and Evernorth, account for a large share of revenue, so a contract renegotiation or loss would be felt immediately. For MCK, the central structural risk is razor-thin distribution margins: on hundreds of billions of revenue McKesson keeps only a small fraction as profit, so even modest cost inflation, contract losses, or generic-pricing deflation can pressure results.

COR or MCK: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick COR if you believe its drivers more; MCK if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the COR and MCK guides.

COR vs MCK: the full fundamentals

COR. The gap between a ~$333 billion top line and a ~$65 billion market value is the whole point of the business model, and reading the revenue figure as a measure of scale in the usual sense will mislead. Cencora keeps roughly four cents of gross profit per dollar of product it moves and a little over one cent of operating profit, so valuation is set off earnings and free cash flow rather than any revenue multiple. At $341.73 the shares trade around 19 times the midpoint of fiscal 2026 adjusted EPS guidance and about 17 times the ~$19.80 analysts expect for fiscal 2027, close to where McKesson and Cardinal Health have traded through the same stretch.

MCK. All figures are approximate and tied to the asOf date; verify live numbers before acting. McKesson reports on a fiscal year ending in March, so the June 2026 quarter is fiscal Q1 2027. Revenue multiples mean little here (about 0.28 times sales); at about $1,004 a share the stock trades near 27 times trailing GAAP earnings and 20 times forward estimates, with analysts modeling adjusted EPS of about $44.66 for fiscal 2027 and $50.63 for fiscal 2028.

Headline figures (approximate, October 2026): COR shows revenue (ttm) ~$333 billion, fiscal q3 2026 revenue ~$84.8 billion, up ~5% year over year, adjusted diluted eps (fy2026 guidance) ~$17.75 to ~$17.95, market capitalization ~$65 billion at ~$341.73; MCK shows revenue (ttm) ~$411 billion (+7.7% YoY latest quarter), margin profile ~3.6% gross, ~1.35% operating, ~1.1% net (distribution dominates revenue), net income (ttm) ~$4.6 billion, adjusted eps (fiscal q1 2027) ~$9.93 vs ~$9.54 est..

The bottom line: COR vs MCK

COR and MCK are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined COR and MCK exposure against your real portfolio. It is not an investment adviser.

Wondering how COR or MCK fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Cencora, Inc.

Ask Walnut's AI anything about COR and see how it fits what you own.

FAQ

What is the difference between COR and MCK?

+

Cencora buys pharmaceuticals from manufacturers and delivers them to pharmacies, hospitals, physician practices and clinics, taking a fee measured in fractions of a percent on each transaction. McKesson Corporation is a healthcare-services and pharmaceutical-distribution company, one of the "Big Three" US drug wholesalers alongside Cencora (formerly AmerisourceBergen) and Cardinal Health that together handle the large majority of prescription drugs sold in the country. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is COR or MCK the better stock?

+

Neither is universally better. MCK is the larger incumbent; COR is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, COR or MCK?

+

On forward P/E (as of November 2026), COR trades at 15.91x and MCK at 20.56x, so COR is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both COR and MCK?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of COR vs MCK?

+

COR: Customer concentration is the sharpest exposure: a small number of relationships, including Walgreens and Evernorth, account for a large share of revenue, so a contract renegotiation or loss would be felt immediately. Opioid litigation obligations are a known and quantified drag rather than an open question: as part of the nationwide distributor settlement announced in 2021, the company (then AmerisourceBergen) agreed to pay roughly $6.4 billion spread over 18 years, and those payments run into the late 2030s alongside a separate $40 million data breach class action settlement resolved in 2025. Margin structure leaves almost no cushion, so a mix shift toward low-fee products such as GLP-1 therapies, or any policy change to drug pricing and reimbursement, compresses profit faster than the revenue line suggests. The move into owning oncology and ophthalmology practices adds integration risk, meaningful debt (including a $3.0 billion notes offering in February 2026 to fund OneOncology), and the possibility of antitrust or regulatory attention to a distributor that also owns providers. A CFO transition completed in mid-2026, with Eva Boratto succeeding James Cleary, adds ordinary execution uncertainty at the top of the finance function. MCK: The central structural risk is razor-thin distribution margins: on hundreds of billions of revenue McKesson keeps only a small fraction as profit, so even modest cost inflation, contract losses, or generic-pricing deflation can pressure results. Customer concentration is real, with a few very large retail-pharmacy customers representing a big share of revenue, giving those partners negotiating leverage. Drug-pricing politics and policy (Medicare negotiation, PBM reform, importation proposals) create ongoing regulatory uncertainty. McKesson also carries a legacy of multibillion-dollar opioid-distribution settlements, and future litigation or regulatory action remains a tail risk. Execution on the Medical-Surgical separation, on integrating oncology and specialty acquisitions, and on the Option Care Health partnership adds transition risk on top of the steady core. GAAP earnings can also swing well away from adjusted figures: GAAP net income was about $614 million in the June 2026 quarter versus about $1.68 billion in the March quarter. Valuation has stretched as well, with the shares up about 21% in three months to above $1,000 and trading near 27 times trailing GAAP earnings.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell COR or MCK; figures are approximate and dated (as of November 2026). Verify current data before investing.